Dr. Ahmad Masri and Dr. C Michael Gibson discuss outpatient worsening heart failure in transthyretin amyloid cardiomyopathy in the Attribute-CM trial
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.
.
Search
Dr. Eugene Brailovsky and Dr. C. Michael Gibson discuss: AF Outcomes and Cardiac Conduction Abnormalities In ATTRibute-CM
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.
Dr. Steve Nissen and Dr. C. Michael Gibson discuss how management is evolving beyond statins alone—highlighting earlier combination therapy, lower LDL-C goals, and expanded roles for non-statin therapy
Sponsored by Esperion Therapeutics Inc., who did not influence the content of the presentation
Dr. Frank Harrell and Dr. C. Michael Gibson talk about the FDA’s new draft guidance on using Bayesian methods in clinical trials—and it could be a game changer.
By allowing researchers to combine prior data with new trial results, these approaches can speed up decision-making, reduce costs, and […]
Dr. Ola Akinboboye and Dr. C. Michael Gibson discuss his recent publication showing that acoramidis has similar efficacy in wild-type and variant transthyretin amyloid cardiomyopathy
Sponsored by an independent educational grant from BridgeBio Pharma Inc.